Key result
Risk-guided cardioprotection may target therapy to highest-benefit patients and avoid unnecessary treatment.
Why the study?
Randomized trials of cardioprotective approaches in patients receiving potentially cardiotoxic cancer therapies have largely selected patients by cancer type and treatment regimen regardless of cardiovascular risk, resulting in modest to no significant benefit on cardiotoxicity measures.
Does a risk-guided cardioprotection approach improve cardiovascular outcomes in patients receiving cardiotoxic cancer therapies compared to standard approaches?
Does a risk-guided cardioprotection approach improve cardiovascular outcomes in patients receiving cardiotoxic cancer therapies compared to standard approaches?
This review highlights the potential of risk-guided cardioprotection to tailor cardiovascular care in cardio-oncology, moving away from a one-size-fits-all approach.
Answers are grounded in this paper and cite their sources.
May inform selective cardioprotection in high-risk patients; leaves open need for randomized validation.
The cardiotoxic effects of cancer therapies are well established, and the most clinically relevant consequences include heart failure and cardiomyopathy. As such, efforts have been focused on developing strategies to attenuate the risk of cardiovascular dysfunction in patients receiving potentially cardiotoxic therapies. Randomized trials to identify cardioprotective approaches have largely selected patients on the basis of cancer type and treatment regimen, regardless of baseline or dynamic changes in cardiovascular risk. However, contemporary evidence suggests that this approach results in modest to no significant benefit on subclinical or clinical measures of cardiotoxicity. We hypothesize that a risk-guided cardioprotection approach can enable the delivery of targeted therapy to those who may derive the greatest cardiovascular benefit, avoiding unnecessary treatment of lower-risk populations. Here, we review the contemporary literature on primary cardioprotection and present recent studies in cardio-oncology focused on risk-guided cardioprotection to support the implementation of more tailored strategies.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) conducted a review in Cancer therapy-induced cardiotoxicity. Risk-guided cardioprotection was evaluated. A risk-guided cardioprotection approach in cardio-oncology may enable the delivery of targeted therapy to patients who derive the greatest cardiovascular benefit, avoiding unnecessary treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: